Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT05208905




Registration number
NCT05208905
Ethics application status
Date submitted
13/01/2022
Date registered
26/01/2022
Date last updated
24/01/2024

Titles & IDs
Public title
LIFE-BTK PK Sub-study
Scientific title
LIFE-BTK Pharmacokinetics (PK) Sub-study
Secondary ID [1] 0 0
ABT-CIP-10293 Ver. B
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Critical Limb Ischemia (CLI) 0 0
Condition category
Condition code
Cardiovascular 0 0 0 0
Other cardiovascular diseases

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Devices - Esprit BTK Device

Experimental: Esprit BTK - Participants who receives Esprit BTK device will be included in this arm


Treatment: Devices: Esprit BTK Device
Participants will receive Esprit BTK Device
Intervention code [1] 0 0
Treatment: Devices
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Time of Maximum (Tmax)
Timepoint [1] 0 0
0 to 60 days
Primary outcome [2] 0 0
Maximum Concentration (Cmax)
Timepoint [2] 0 0
0 to 60 days
Primary outcome [3] 0 0
AUC0-24h
Timepoint [3] 0 0
0 to 24 hours
Primary outcome [4] 0 0
AUC Last/AUC0-t
Timepoint [4] 0 0
0 to 60 days
Primary outcome [5] 0 0
AUC 0-infinity
Timepoint [5] 0 0
0 to 60 days
Primary outcome [6] 0 0
Terminal Elimination Rate Constant (?z)
Timepoint [6] 0 0
0 to 60 days
Primary outcome [7] 0 0
Terminal Elimination Half-life (t1/2term)
Timepoint [7] 0 0
0 to 60 days
Primary outcome [8] 0 0
Drug Clearance (CL)
Timepoint [8] 0 0
0 to 60 days

Eligibility
Key inclusion criteria
General

1. Subject must provide written informed consent prior to any clinical investigation
related procedure

2. Subject has symptomatic Critical Limb Ischemia (CLI), Rutherford Becker Clinical
Category 4 or 5

3. Subject requires primary treatment of one or more de novo or restenotic (treated with
prior PTA) infrapopliteal lesions

4. Subject must be at least 18 years of age

5. Female subject of childbearing potential should not be pregnant and must be on birth
control Note: Female subjects of child-bearing potential must have a negative
pregnancy test done within 7 days prior to the index procedure per site standard test.

Anatomic

1. One or more native infrapopliteal lesions, including de novo lesions in the same limb.
Restenotic (from prior PTA) lesions are allowed.

1. Lesion must be located in the proximal 2/3 of native infrapopliteal vessels, with
vessel diameter of = 2.5 mm and = 4.00 mm by investigator visual assessment.

2. Total scaffold length to completely cover/treat target lesion(s) must be between
170 and 256 mm (maximum total everolimus drug dose of 2714 µg).

3. The target vessel can have any other angiographic significant lesions (=50%) that
should be treated per institution standard of care prior to treatment of the
target lesion.

4. Tandem lesions are allowed and the total scaffold length used to cover the entire
diseased segment must be = 256 mm.

2. Target lesion(s) must have = 70% stenosis, per visual assessment at the time of the
procedure. If needed, quantitative imaging (angiography, IVUS, and/or OCT) can be used
to aid accurate sizing of the vessels.

3. The distal margin of the scaffold must be located = 10 cm proximal to the proximal
margin of the ankle mortise. If the vessel segment distal to the target lesion has a
significant lesion (> 50% stenosis), it should be treated per institution standard of
care prior to deployment of the scaffold.

4. Significant lesion (= 50% stenosis) in the inflow artery(ies) must be treated
successfully (as per physician's assessment of the angiography) through standard of
care prior to the treatment of the target lesion. Treatment must be done within the
same trial procedure. Treatment allowed for inflow artery lesions are PTA,
atherectomy, cutting/scoring balloon, Shockwave balloon, bare metal stent,
drug-eluting stents or drug-coated balloon. Everolimus-coated or eluting devices are
not allowed.

5. It is acceptable for non-target lesion(s) (if applicable) to be located in the same
infrapopliteal vessel(s) as the target lesion, and suitable to be treated per
institution standard of care. Non-target lesions must be treated successfully prior to
target lesions and not requiring re-cross of the scaffold.

6. Crossing of the target lesion in an antegrade fashion is preferred, but retrograde
crossing may be used. However, the treatment must be delivered antegrade.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
General

1. Subject is currently participating in another clinical investigation that has not yet
completed its primary endpoint.

2. Pregnant or nursing subjects and those who plan pregnancy during the clinical
investigation follow-up period.

3. Presence of other anatomic or comorbid conditions, or other medical, social, or
psychological conditions that, in the investigator's opinion, could limit the
subject's ability to participate in the clinical investigation or to comply with
follow-up requirements.

4. Incapacitated individuals, defined as persons who are mentally ill, mentally
handicapped, or individuals without legal authority, are excluded from the study
population.

5. Subject has had any amputation to the ipsilateral extremity other than the toe or
forefoot, or subject has had major amputation to the contralateral extremity < 1 year
prior to index procedure and is not independently ambulating.

6. Subject has known hypersensitivity or contraindication to device material and its
degradants (everolimus, poly (L-lactide), poly (DL-lactide), lactide, lactic acid) and
cobalt, chromium, nickel, platinum, tungsten, acrylic and fluoro polymers that cannot
be adequately pre-medicated. Subject has a known contrast sensitivity that cannot be
adequately pre-medicated.

7. Subject has known allergic reaction, hypersensitivity or contraindication to aspirin;
or to ADP antagonists such clopidogrel, prasugrel or ticagrelor; or to anticoagulants
such as heparin or bivalirudin, and therefore cannot be adequately treated with study
medications. Subject with planned surgery or procedure necessitating discontinuation
of antiplatelet medications, within 12 months after index procedure. Planned
amputation that will necessitate discontinuation of antiplatelet medications is
allowed.

8. Subject has life expectancy = 1 year.

9. Subject has had a stroke within the previous 3 months with residual Rankin score of =
2.

10. Subject has renal insufficiency as defined as an estimated GFR < 30 ml/min per
1.73m^2.

11. Subject is currently on dialysis.

12. Subject has platelet count < 100,000 cells/mm^3 or > 700,000 cells/mm^3, a WBC < 3,000
cells/mm^3, or hemoglobin < 9.0 g/dl.

13. Subject has known serious immunosuppressive disease (e.g., human immunodeficiency
virus), or has severe autoimmune disease, that requires chronic immunosuppressive
therapy (e.g., systemic lupus erythematosus, etc.), or subject is receiving
immunosuppression therapy for other conditions. Subjects treated for HIV (Human
Immunodeficiency Virus) and who have undetectable viral load, such that their immune
system is not considered compromised, are eligible.

14. Subject has Body Mass Index (BMI) <18.

15. Subject is receiving or scheduled to receive anticancer therapy for malignancy within
6 months prior to index procedure or within 1 year after the procedure. Patients
taking medications classified as chemotherapy but who have been in remission for at
least 6 months are eligible.

16. Subject has coagulation disorder that increases the risk of arterial thrombosis.
Subjects with deep vein thrombosis and disorders that increase the risk of deep vein
thrombosis can be included in the study.

17. Subject who requires thrombolysis as a primary treatment modality or requires other
treatment for acute limb ischemia of the target limb.

18. Subject has previously had, or requires surgical revascularization involving any
vessel of the ipsilateral extremity. Prior femoropopliteal or aortobifemoral bypass is
allowed. Any bypass to the tibial arteries is not allowed.

19. Subject has signs or symptoms of advanced limb infection or septicemia (fever > 38.5,
WBC > 15,000 cells/microliter, hypotension) at the time of assessment. Osteomyelitis
of the phalanges or metatarsal heads (as described in exclusion criteria #21a) or
cellulitis of the foot amenable to treatment with IV antibiotics at the time of
revascularization is acceptable.

20. Subject is bedridden or unable to walk (with assistance is acceptable). Subjects in
wheelchair who are able to mobilize on their own can be enrolled.

21. Subject with extensive tissue loss salvageable only with complex foot reconstruction
or non-traditional transmetatarsal amputations. This includes subjects with:

1. Osteomyelitis that extends proximal to the metatarsal heads. Osteomyelitis
limited to the phalanges or metatarsal heads is acceptable for enrollment.

2. Gangrene involving the plantar skin of the forefoot, midfoot, or heel

3. Deep ulcer or large shallow ulcer (> 3 cm) involving the plantar skin of the
forefoot, midfoot, or heel

4. Full thickness heel ulcer with/without calcaneal involvement

5. Any wound with calcaneal bone involvement

6. Wounds that are deemed to be neuropathic or non-ischemic in nature

7. Wounds that would require flap coverage or complex wound management for large
soft tissue defect

8. Full thickness wounds on the dorsum of the foot with exposed tendon or bone.

22. Subject is unable or unwilling to provide written consent prior to enrollment

23. Subject has active symptoms and/or a positive test result of COVID-19 or other rapidly
spreading novel infectious agent within the prior 2 months

Anatomic

1. Lesions with severe calcification, in which there is a high likelihood that successful
pre-dilatation cannot be achieved.

2. Lesion that has prior metallic stent implant.

3. Coronary or peripheral artery treated with everolimus-eluting device during index
procedure, or within 90 days prior to index procedure.

4. Target or (if applicable) non-target vessel contains visible thrombus as indicated in
the angiographic images.

5. Subject has angiographic evidence of thromboembolism or atheroembolism in the
ipsilateral extremity. (Pre- and post-angiographic imaging must confirm the absence of
emboli in the distal anatomy.)

6. Unsuccessfully treated proximal inflow limiting arterial stenosis or inflow-limiting
arterial lesions left untreated.

7. No angiographic evidence of a patent pedal artery.

8. Target or (if applicable) non-target lesion location requiring bifurcation treatment
method that requires scaffolding of both branches (provisional treatment, without
intention of scaffolding both branches is acceptable).

9. Aneurysm in the iliac, common femoral, superficial femoral, popliteal or target artery
of the ipsilateral extremity.

10. Visual assessment of the target lesion suggests that the investigator is unable to
pre-dilate the lesion according to the vessel diameter.

11. Target lesion has a high probability that atherectomy will be required at the time of
index procedure for treatment of the target vessel.

Note: staged procedures are not allowed in LIFE-BTK PK sub-study.

Study design
Purpose of the study
Treatment
Allocation to intervention
N/A
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Not Applicable
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
10/02/2022
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
22/02/2028
Actual
Sample size
Target
Accrual to date
Final
9
Recruitment in Australia
Recruitment state(s)
WAU
Recruitment hospital [1] 0 0
Sir Charles Gairdner Hospital - Nedlands
Recruitment postcode(s) [1] 0 0
- Nedlands
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Florida
Country [2] 0 0
United States of America
State/province [2] 0 0
Massachusetts
Country [3] 0 0
United States of America
State/province [3] 0 0
Oklahoma
Country [4] 0 0
Taiwan
State/province [4] 0 0
Taipei

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Abbott Medical Devices
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
LIFE-BTK PK is a prospective, single-arm, open-label, non-blinded, non-randomized sub-study
of LIFE-BTK Randomized Controlled Trial (NCT04227899), that will enroll approximately 7
subjects in the United States (US) and outside the US with a maximum of 5 sites in the US. Of
the 7 subjects planned to be enrolled, 4 subjects will be treated with Esprit BTK in below
the knee artery(ies) in whom drug-coated balloons (DCB) were not used; 3 subjects will be
treated with Esprit BTK in below the knee artery(ies) in whom DCB were used for treatment of
inflow disease.
Trial website
https://clinicaltrials.gov/ct2/show/NCT05208905
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries